多西紫杉醇治疗激素抵抗型前列腺癌研究进展

前列腺癌为西方国家最常见的恶性肿瘤,对于预后较差的激素抵抗型前列腺癌(HRPC),目前主要的治疗方法是化疗。米托蒽醌、磷雌氮芥和多西紫杉醇都是已经FDA批准用于前列腺癌的化疗药物,其中多西紫杉醇被认为是目前惟一对HRPC有生存益处的药物,具有较好的临床应用前景。多项以多西紫杉醇为基础的联合化疗临床试验正在进行中,其目的在于寻求更为安全和有效的治疗方案。

Progress of docetaxel in the treatment of Hormone Refractory Prostatic Carcinoma

Prostatic cancer is the most common malignant tumor in western country,in which the main therapy of hormone refractory prostatic carcinoma is chemotherapy.The most frequently used chemotherapeutic agents are mitoxantrone and estramustine and docetaxel which have been approved by FDA.But docetaxel is considered as the only one drug benificial to survival time at present,and have a better clinical future.Many clinical experiment of combination chemotherapy based on docetaxel is undergoing in order to seek the more safty and effective therapeutic method.